← Leaderboards
James Richard Gossage
Hht Foundation International, Inc.
$877,822
Attributed
$877,822
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $478.5K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
FDA$877,822 · 1
By mechanism
R01$877,822 · 1
Top collaborators
No co-investigators on record.
Grant awards (3)
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020$180,854
R01 · FY2025 · FD · contact PI
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020$218,460
R01 · FY2024 · FD · contact PI
A Phase II/III randomized, placebo controlled, double blind study to evaluate the effects of up to 24 weeks of low dose pazopanib on HHT related epistaxis and anemia. IND#144808 June 25, 2020$478,508
R01 · FY2022 · FD · contact PI